A study of long-term efficacy and safety of calcipqotriol hydrate/betamethasone dipropionate ester fixed dose combination product in patients with psoriasis vulgaris
Phase 4
- Conditions
- psoriasis vulgaris
- Registration Number
- JPRN-UMIN000025083
- Lead Sponsor
- Fukuoka University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) pregnant, or possibly pregnant women 2) subjects contraindicated by package insert 3) subjects judged unsuitable by physicians 4) subjects who are going to receive oral or injective steroid, cyclosporine, methotrexate, biologics, ultraviolet therapy, herbal medication against psoriasis within the trial period., 5) subjects who used Dovobet within 4 weeks before starting the trial.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method comparison of m-PASI score at week 0, week 4, week24, and week52.
- Secondary Outcome Measures
Name Time Method PGA and safety